0001968202-24-000028.txt : 20240104
0001968202-24-000028.hdr.sgml : 20240104
20240104161118
ACCESSION NUMBER: 0001968202-24-000028
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zoghbi Huda Y
CENTRAL INDEX KEY: 0001681643
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 24511970
MAIL ADDRESS:
STREET 1: REGENERON PHARMACEUTICALS, INC.
STREET 2: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-01-02
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001681643
Zoghbi Huda Y
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
1
Common Stock
2024-01-02
4
M
0
1117
391.92
A
2364
D
Common Stock
2024-01-02
4
S
0
1117
900.0
D
1247
D
Common Stock
2024-01-02
4
A
0
135
0.0
A
1382
D
Non-Qualified Stock Option (right to buy)
391.92
2024-01-02
4
M
0
1117
0.0
D
2026-09-09
Common Stock
1117
0
D
Non-Qualified Stock Option (right to buy)
888.34
2024-01-02
4
A
0
1607
0.0
A
2034-01-02
Common Stock
1607
1607
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.
Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
/s/**Huda Y. Zoghbi
2024-01-04